Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03385564 · ClinicalTrials.gov registry record · Phase 2
An Exploratory Maintenance Trial of BI 655064 in Patients With Lupus Nephritis
A Phase 2 study, sponsored by Boehringer Ingelheim.
- Completed
- Registry status
- Phase 2
- Development phase
- 69
- Enrollment target
NCT03385564 is a Phase 2 study that has completed, run by Boehringer Ingelheim. The registered enrollment target is 69 participants.
The verdict
NCT03385564, a Phase 2 study, has completed, sponsored by Boehringer Ingelheim.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 69 participants
- Enrollment target
Study Summary
The main objectives of this trial are to evaluate the long term efficacy and safety of different doses of BI 655064 versus placebo as add-on therapy to Standard of Care (SOC) during maintenance therapy for lupus nephritis.
Interventions
- DRUG Placebo
- DRUG BI 655064
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 69 participants |
| Start Date | 2018-01-09 |
| Est. Completion | 2021-07-27 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03385564
The ClinicalTrials.gov registry entry for NCT03385564 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 69 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Boehringer Ingelheim, which has 515 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.
NCT03385564 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT03385564 about?
NCT03385564 is a clinical study titled "An Exploratory Maintenance Trial of BI 655064 in Patients With Lupus Nephritis". The main objectives of this trial are to evaluate the long term efficacy and safety of different doses of BI 655064 versus placebo as add-on therapy to Standard of Care (SOC) during maintenance therapy for lupus nephritis.
What is the current status of trial NCT03385564?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 69 participants. The study started on 2018-01-09. Estimated completion is 2021-07-27.
What interventions are being tested in trial NCT03385564?
The interventions under investigation include: Placebo (DRUG), BI 655064 (DRUG).
Who is sponsoring clinical trial NCT03385564?
This trial is sponsored by Boehringer Ingelheim, which has 515 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.